[
1. KİM Y, AHN E, LEE S, LİM DH, KİM A, LEE SG., et al. Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic. J Korean Med Sci. 2020;35(48):e423.10.3346/jkms.2020.35.e423
]Search in Google Scholar
[
2. HASÖKSÜZ M, KİLİÇ S, SARAÇ F. Coronaviruses and SARS-CoV-2. Turkish journal of medical sciences. 2020;50(SI-1):549–56.10.3906/sag-2004-127
]Search in Google Scholar
[
3. POPE JE. What does the COVID-19 pandemic mean for rheumatology patients? Current treatment options in rheumatology. 2020;6(2):71–4.10.1007/s40674-020-00145-y
]Search in Google Scholar
[
4. RİCHEZ C, LAZARO E, LEMOİNE M, TRUCHETET M-E, SCHAEVERBEKE T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine. 2020;87(3):187.10.1016/j.jbspin.2020.03.010
]Search in Google Scholar
[
5. SAADOUN D, VİEİRA M, VAUTİER M, BARALİAKOS X, ANDREİCA I, DA SİLVA JA., et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. The Lancet Rheumatology. 2021.10.1016/S2665-9913(21)00112-0
]Search in Google Scholar
[
6. PABLOS JL, GALİNDO M, CARMONA L, LLEDÓ A, M RETUERTO, BLANCO R., et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis, 2020. 79(12): p. 1544–1549.10.1136/annrheumdis-2020-218296743018532796045
]Search in Google Scholar
[
7. MONTERO F, MARTÍNEZ-BARRİO J, SERRANO-BENAVENTE B, GONZÁLEZ T, RİVERA J, MOLİNA COLLADA J., et al. Coronavirusdisease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int, 2020. 40(10): p. 1593–1598.10.1007/s00296-020-04676-4742525432794113
]Search in Google Scholar
[
8. SANTOS CS, FÉRNANDEZ XC, MORALES CM, ÁLVAREZ ED, CASTRO CÁ, ROBLES AL., et al. Biologicalagentsforrheumaticdiseases in theoutbreak of COVID-19: friendorfoe? RMD Open, 2021. 7(1).10.1136/rmdopen-2020-001439781340733455920
]Search in Google Scholar
[
9. Turkish Rheumatology Association Coronavirus (Covid-19) Outbreak Recommendations (2020) March 27th Title.
]Search in Google Scholar
[
10. GABRİEL SE, MİCHAUD K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis research & therapy. 2009;11(3):229.10.1186/ar2669271409919519924
]Search in Google Scholar
[
11. SFRİSO P, GHİRARDELLO A, BOTSİOS C, TONON M, ZEN M, BASSİ N., et al. Infections and autoimmunity: the multifaceted relationship. Journal of leukocyte biology. 2010;87(3):385–95.10.1189/jlb.070951720015961
]Search in Google Scholar
[
12. GİRSCHİCK HJ, GUİLHERME L, INMAN RD, LATSCH K, RİHL M, SHERER Y., et al. Bacterial triggers and autoimmune rheumatic diseases. Clinical and experimental rheumatology. 2008;26(1 Suppl 48):S12–7.
]Search in Google Scholar
[
13. SEYAHİ E, POYRAZ BC, SUT N, AKDOGAN S, HAMURYUDAN V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatol Int. 2020;40(8):1229–38.10.1007/s00296-020-04626-0
]Search in Google Scholar
[
14. European League Against Rheumatism (EULAR), Guidance for Patients during Covid-19 Outbreak, (2020) Updated March 17th Internet.https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm. April 25th, 2020
]Search in Google Scholar
[
15. American College of Rheumatology (Acr), Guidance for Patients during Covid-19Outbreak, (2020) Updated April 14th.
]Search in Google Scholar
[
16. British Society for Rheumatology (Bsr), Guidance for Patients during Covid-19 Outbreak, (2020) Updated July 29th.
]Search in Google Scholar
[
17. VENERİTO V, LOPALCO G, IANNONE F. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatology international. 2020;40(5):827–8.10.1007/s00296-020-04566-9
]Search in Google Scholar
[
18. COSKUN BN, YAGİZ B, PEHLİVAN Y, DALKİLİC E. Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Advances in rheumatology (London, England). 2021;61(1):55.10.1186/s42358-021-00211-6
]Search in Google Scholar
[
19. FAVALLİ EG, MONTİ S, INGEGNOLİ F, BALDUZZİ S, CAPORALİ R, MONTECUCCO C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis & Rheumatology. 2020;72(10):1600–6.10.1002/art.41388
]Search in Google Scholar
[
20. ROSENBAUM JT, HAMİLTON H, CHOİ D, WEİSMAN MH, REVEİLLE JD, WİNTHROP KL. Biologics, spondylitis and COVID-19. Annals of the rheumatic diseases. 2020;79(12):1663–5.10.1136/annrheumdis-2020-217941
]Search in Google Scholar
[
21. LÓPEZ-MEDİNA C, LADEHESA-PİNEDA L, GÓMEZ-GARCÍA I, PUCHE-LARRUBİA M, SEQUÍ-SABATER JM, ARMENTEROS-ORTİZ P., et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. Joint Bone Spine. 2021;88(2):105085.10.1016/j.jbspin.2020.105085
]Search in Google Scholar
[
22. KALYONCU U, PEHLİVAN Y, AKAR S, KAŞİFOĞLU T, KİMYON G, KARADAĞ Ö., et al. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish journal of medical sciences. 2021;51(4):1615–23.10.3906/sag-2012-5
]Search in Google Scholar
[
23. COSTANTİNO F, BAHİER L, TARANCÓN LC, LEBOİME A, VİDAL F, BESSALAH L., et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. 2021;88(1):105095.10.1016/j.jbspin.2020.105095
]Search in Google Scholar
[
24. LANDEWÉ RB, MACHADO PM, KROON F, BİJLSMA HW, BURMESTER GR, CARMONA L., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the rheumatic diseases. 2020;79(7):851–8.10.1136/annrheumdis-2020-217877
]Search in Google Scholar
[
25. MEHTA P, PORTER JC, CHAMBERS RC, ISENBERG DA, REDDY V. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? The Lancet Rheumatology. 2020;2(10):e589–e90.10.1016/S2665-9913(20)30270-8
]Search in Google Scholar
[
26. EMMİ G, BETTİOL A, MATTİOLİ I, SİLVESTRİ E, Dİ SCALA G, URBAN ML., et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev, 2020. 19(7): p. 102575.10.1016/j.autrev.2020.102575720013432376395
]Search in Google Scholar
[
27. STRANGFELD A, SCHÄFER M, GİANFRANCESCO MA, LAWSON-TOVEY S, LİEW JW, LJUNG L., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–42.10.1136/annrheumdis-2020-219498784321133504483
]Search in Google Scholar
[
28. TEPASSE PR, HAFEZİ W, LUTZ M, KÜHN J, WİLMS C, WİEWRODT R., et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. British journal of haematology. 2020;190(2):185–8.10.1111/bjh.16896730095032557623
]Search in Google Scholar
[
29. ZHAO J, YUAN Q, WANG H, LİU W, LİAO X, SU Y., et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(16):2027–34.10.1093/cid/ciaa344718433732221519
]Search in Google Scholar
[
30. SCHETT G, MANGER B, SİMON D, CAPORALİ R. COVID-19 revisiting inflammatory pathways of arthritis. Nature Reviews Rheumatology. 2020:1-6.10.1038/s41584-020-0451-z730438132561873
]Search in Google Scholar
[
31. CAMPBELL L, CHEN C, BHAGAT SS, PARKER RA, ÖSTÖR AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford, England). 2011;50(3):552–62.10.1093/rheumatology/keq34321078627
]Search in Google Scholar
[
32. CARRARA G, BORTOLUZZİ A, SAKELLARİOU G, SİLVAGNİ E, ZANETTİ A, GOVONİ M., et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clinical and experimental rheumatology. 2019;37(1):60–6.
]Search in Google Scholar
